Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.71 |
| ▸ | CNR2 | P34972 | 1/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2007083 | 0.99 | PTGS2 (0.74) | PTGS2PTGS1MAPTKMT2ANPSR1 | |
| SCHEMBL2009989 | 0.95 | PTGS2 (0.73) | PTGS2PTGS1HRH4AKR1C3 | |
| SCHEMBL2003866 | 0.95 | PTGS2 (0.73) | PTGS2PTGS1MAPTKMT2ANPSR1 | |
| SCHEMBL2009741 | 0.92 | PTGS2 (0.77) | PTGS2PTGS1MAPTKMT2ANPSR1 | |
| SCHEMBL2009164 | 0.91 | PTGS2 (0.79) | PTGS2PTGS1HRH4 | |
| SCHEMBL2008613 | 0.91 | PTGS2 (0.78) | PTGS2PTGS1MAPTKMT2ANPSR1 | |
| SCHEMBL2009259 | 0.89 | PTGS2 (0.73) | PTGS2PTGS1HRH4 | |
| SCHEMBL2002654 | 0.88 | PTGS2 (0.74) | PTGS2PTGS1MAPTKMT2ANPSR1 | |
| SCHEMBL2006381 | 0.88 | PTGS2 (0.73) | PTGS2PTGS1HRH4 | |
| SCHEMBL2007301 | 0.87 | PTGS2 (0.77) | PTGS2PTGS1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129331-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | RND PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | claimed |
| EP-1737471-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | RND Pharmaceuticals (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2005102358-A2 | SILICONE-SUBSTITUTED COX-2 SELECTIVE INHIBITORS | RND PHARMACEUTICALS (US) | 2005-11-03 | — | — | WO | claimed |
| US-7964738-B2 | Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives | SILAMED, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20070129331-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | RND PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129331-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | PTGES2, PTGS2, SI | PTGS2 2/4885PTGS1 5/4885MAPT 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.